Evaluation of Five Staging Systems in 470 Patients with Multiple Myeloma

Overview

Journal Haematologica

Specialty Hematology

Date 2006 Aug 4

PMID 16885059

Citations 5

Authors

Dimitra Mihou

Irene Katodritou

Kostas Zervas

Affiliations

Soon will be listed here.

Abstract

We evaluated the prognostic significance of five staging systems in 470 consecutive, previously untreated patients with multiple myeloma diagnosed between 1989 and 2006. The five staging systems were those proposed by Durie and Salmon, Bataille et al., the South West Oncology Group, Weber et al. and the International Staging System. This last proved to be superior to the others.

Citing Articles

Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment.

Cerchione C, Usmani S, Stewart A, Kaiser M, Rasche L, Kortum M Front Oncol. 2022; 12:820768.

PMID: 35211412 PMC: 8861274. DOI: 10.3389/fonc.2022.820768.

[Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10].

Zhao J, Jiang X, Yang C, Chen M, Lan X, Du J Zhonghua Xue Ye Xue Za Zhi. 2021; 42(4):295-301.

PMID: 33979973 PMC: 8120119. DOI: 10.3760/cma.j.issn.0253-2727.2021.04.005.

The Role of F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie-Salmon Plus and Other Staging Systems.

Deng S, Zhang B, Zhou Y, Xu X, Li J, Sang S Contrast Media Mol Imaging. 2018; 2018:4198673.

PMID: 30154686 PMC: 6091330. DOI: 10.1155/2018/4198673.

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.

Richardson P, Mitsiades C, Laubach J, Schlossman R, Ghobrial I, Hideshima T Core Evid. 2010; 4:215-45.

PMID: 20694078 PMC: 2899783. DOI: 10.2147/ce.s6002.

Clinical value of new staging systems for multiple myeloma.

Choi J, Yoon J, Yang S Cancer Res Treat. 2009; 39(4):171-4.

PMID: 19746184 PMC: 2739370. DOI: 10.4143/crt.2007.39.4.171.